COVID-19 Treatment GuidelinesPage 11 of 15

9. Immunomodulators

*This course has been retired. Please click here for new course: COVID NIH Treatment Guidelines.

Summary

A doctor explaining what's new in COVID-19 treatment.

U.S. Department of Health and Human Services

The hyperactive inflammatory response to SARS-CoV-2 infection plays a central role in the pathogenesis of COVID-19. This section includes information on the use of the following immunomodulators for hospitalized patients, depending on disease severity: corticosteroids: (dexamethasone); Interleukin-6 inhibitors: (tocilizumab or sarilumab); Janus kinase (JAK) inhibitors: baricitinib (or tofacitinib). 

This section includes additional recommendations about other immunomodulators with insufficient information to make a recommendation and guidance about immunomodulators that the Panel recommends against.

Instructions

  1. Click on the PDF link below to access this section.
  2. Return to this page. Click “Next” below access the next section.
  3. The last section provides a link to the quiz, registration, payment, and certificate.

PDF icon Section 9: Immunomodulators

Back Next